Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 547

1.

KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.

Zhu MJ, Ou WB, Fletcher CD, Cohen PS, Demetri GD, Fletcher JA.

Oncogene. 2007 Sep 27;26(44):6386-95. Epub 2007 Apr 23.

PMID:
17452978
2.
3.

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA.

J Clin Oncol. 2003 Dec 1;21(23):4342-9.

PMID:
14645423
4.

Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.

Prenen H, Cools J, Mentens N, Folens C, Sciot R, Schöffski P, Van Oosterom A, Marynen P, Debiec-Rychter M.

Clin Cancer Res. 2006 Apr 15;12(8):2622-7.

5.

Strong PDGFRA positivity is seen in GISTs but not in other intra-abdominal mesenchymal tumors: Immunohistochemical and mutational analyses.

Peterson MR, Piao Z, Weidner N, Yi ES.

Appl Immunohistochem Mol Morphol. 2006 Dec;14(4):390-6.

PMID:
17122634
6.

PDGFRA activating mutations in gastrointestinal stromal tumors.

Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA.

Science. 2003 Jan 31;299(5607):708-10. Epub 2003 Jan 9.

7.

Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs).

Duensing A, Medeiros F, McConarty B, Joseph NE, Panigrahy D, Singer S, Fletcher CD, Demetri GD, Fletcher JA.

Oncogene. 2004 May 13;23(22):3999-4006.

PMID:
15007386
8.

Pathology of gastrointestinal stromal tumors.

Hirota S, Isozaki K.

Pathol Int. 2006 Jan;56(1):1-9. Review.

PMID:
16398673
9.

KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.

Bauer S, Duensing A, Demetri GD, Fletcher JA.

Oncogene. 2007 Nov 29;26(54):7560-8. Epub 2007 Jun 4.

PMID:
17546049
10.

KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).

Lasota J, Miettinen M.

Semin Diagn Pathol. 2006 May;23(2):91-102. Review.

PMID:
17193822
11.

Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms.

Tarn C, Skorobogatko YV, Taguchi T, Eisenberg B, von Mehren M, Godwin AK.

Cancer Res. 2006 May 15;66(10):5477-86.

12.

Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.

Zheng S, Chen LR, Wang HJ, Chen SZ.

Hepatogastroenterology. 2007 Dec;54(80):2285-90.

PMID:
18265649
13.

Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs).

Duensing A, Joseph NE, Medeiros F, Smith F, Hornick JL, Heinrich MC, Corless CL, Demetri GD, Fletcher CD, Fletcher JA.

Cancer Res. 2004 Aug 1;64(15):5127-31.

14.

Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.

Yeh CN, Chen TW, Lee HL, Liu YY, Chao TC, Hwang TL, Jan YY, Chen MF.

Ann Surg Oncol. 2007 Mar;14(3):1123-8. Epub 2006 Dec 31.

PMID:
17195905
15.

Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.

Lasota J, Miettinen M.

Histopathology. 2008 Sep;53(3):245-66. doi: 10.1111/j.1365-2559.2008.02977.x. Epub 2008 Feb 28. Review.

PMID:
18312355
16.

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.

Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, Shiraga S, Bainbridge T, Morich J, Heinrich MC.

J Clin Oncol. 2005 Aug 10;23(23):5357-64. Epub 2005 May 31. Review.

PMID:
15928335
17.

Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs).

Negri T, Bozzi F, Conca E, Brich S, Gronchi A, Bertulli R, Fumagalli E, Pierotti MA, Tamborini E, Pilotti S.

J Pathol. 2009 Jan;217(1):103-12. doi: 10.1002/path.2450.

PMID:
18973210
18.

Site-dependent differential KIT and PDGFRA expression in gastric and intestinal gastrointestinal stromal tumors.

Haller F, Happel N, Schulten HJ, von Heydebreck A, Schwager S, Armbrust T, Langer C, Gunawan B, Doenecke D, Füzesi L.

Mod Pathol. 2007 Oct;20(10):1103-11. Epub 2007 Aug 3.

19.

Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.

Lim KH, Huang MJ, Chen LT, Wang TE, Liu CL, Chang CS, Liu MC, Hsieh RK, Tzen CY.

Med Oncol. 2008;25(2):207-13. doi: 10.1007/s12032-007-9014-2. Epub 2007 Oct 6.

PMID:
18488160
20.

Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.

Hayashi Y, Bardsley MR, Toyomasu Y, Milosavljevic S, Gajdos GB, Choi KM, Reid-Lombardo KM, Kendrick ML, Bingener-Casey J, Tang CM, Sicklick JK, Gibbons SJ, Farrugia G, Taguchi T, Gupta A, Rubin BP, Fletcher JA, Ramachandran A, Ordog T.

Gastroenterology. 2015 Aug;149(2):420-32.e16. doi: 10.1053/j.gastro.2015.04.006. Epub 2015 Apr 9.

Items per page

Supplemental Content

Write to the Help Desk